
    
      A multicentre, randomized, open label, two parallel group study The patients will be
      randomized to MR4 group or PrografÂ® group. The treatment period is 3 months( 12
      weeks).Patients randomized to MR4 group who complete 3 months treatment period will continue
      to use MR4 until MR4 commercial available or authority notification.
    
  